MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
16 mai 2024 07h00 HE | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
15 mai 2024 16h01 HE | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
09 mai 2024 07h00 HE | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics today reported business highlights and financial results for the first quarter ending March 31, 2024.
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer
02 mai 2024 16h01 HE | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
14 mars 2024 07h00 HE | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor
11 mars 2024 07h00 HE | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7-Directed Molecular Glue Degrader
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
31 janv. 2024 07h00 HE | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
08 janv. 2024 07h15 HE | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 07h00 HE | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference
21 nov. 2023 07h00 HE | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference